ClinicalTrials.gg
RecruitingNCT06748950Updated Nov 16, 2026

Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

An interventional study of LCHF Ketogenic Diet and Diet-as-Usual (DAU) in Schizophrenia, Schizophrenia and Related Disorders and Bipolar Disorder, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Planned enrollment
431st of 1,320
120 · median 66
Started
2026
with 49 others
No phase
480 of 1,466
72 open now
Primary completion
2028-12
later than 122 of 165 live
Registered
1,371st of 1,466
by date

Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 431st largest by planned enrollment of the 1,320 interventional ones that give a count, is one of 50 that started in 2026, is one of 480 with no phase, reaches primary completion later than 122 of the 165 other live ones, and was the 1,371st registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

142 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,466 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive disorder.

Read the detailed description

The ketogenic diet is a low carbohydrate, moderate protein, higher fat diet to help individuals improve energy and mood and to obtain nutrients from fats and protein. Schizophrenia, bipolar disorder, and major depressive disorder, collectively affect about 344 million individuals worldwide, (24 million with schizophrenia, 40 million people with BD, and 280 million with depression World Health Organization). These illnesses are debilitating psychiatric conditions characterized by a chronic pattern of emotional, behavioral, and cognitive disturbances. Shared psychopathology includes the pre-eminence of altered affective states, disorders of thoughts, and behavioral control. Additionally, those conditions share epidemiological traits, including significant cardiovascular, metabolic, infectious, and respiratory comorbidities, resulting in reduced life expectancy of up to 25 years (Xie et al., 2023). Reductions in cerebral glucose uptake are seen in both schizophrenia and bipolar disorder. While glucose is the brain's default fuel, ketone bodies are 27% more efficient, improve brain metabolism, and promote neural stability, as seen in childhood epilepsy (Sethi \& Ford, 2022). The ketogenic diet (KD, also known as metabolic therapy) has been successful in the treatment of obesity, type 2 diabetes, and epilepsy (Sethi et al., 2024, Liu et al., 2018, Martin-McGill et al., 2020). Nutritional ketosis has been successfully used to treat a range of neurological disorders. Metabolic disorders, which include conditions such as obesity and metabolic syndrome, more commonly occur in individuals with severe mental illness (between 40-60%). The investigators aim to study the effect of ketogenic metabolic therapy on various markers including:

  • Metabolic health measurements and cardiovascular risk factors including: insulin resistance, advanced lipid analysis, weight, glucose regulation, dyslipidemia, absolute body fat chang, inflammation, waist circumference, blood pressure, skeletal muscle mass, and omega index
  • Psychiatric symptom measures include: mood, psychosis, cognition, and quality of life
  • Deep omic profiling including metabolic and proteomic data. Through identifying patterns, changes, and pathways of molecular, psychiatric, physiologic, and metabolic markers, the investigators aim to assess how this intervention may impact individuals with serious mental illnesses and symptoms/conditions related to serious mental illnesses.
03

Conditions studied

  • Schizophrenia
  • Schizophrenia and Related Disorders
  • Bipolar Disorder
  • Bipolar and Related Disorders
  • Major Depressive Disorder
  • Major Depression Severe
  • Ketogenic Dieting
  • Ketosis
  • Metabolic Disease
  • Metabolic Syndrome

Keywords

  • Mental Illness
  • Multiomics
  • Multi-omics
  • Omics Profiling
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosed with bipolar disorder (BD), major depressive disorder (MDD), and or schizophrenia

    1. For individuals diagnosed with bipolar disorder (BD):

      • Meet DSM V criteria for BD (any subtype)
      • clinically stable (with no hospitalization for past 3 months)
    2. For individuals diagnosed with major depressive disorder (MDD):

      • clinically stable (with no hospitalization for past 3 months)
    3. For individuals diagnosed with schizophrenia:

      • Meet DSM V criteria for schizophrenia (any subtype)
      • clinically stable (with no hospitalization for past 3 months)
  2. Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy or other psychiatric medication. Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least four weeks prior to screening and if it is expected to remain stable. Participants may be switched from other classes of medication to another medication class by their psychiatrist or primary care doctor, but need to be stable enough to enroll and adhere to study procedures.
  3. willing and able to give for participation in English.
  4. live within the United States.

    --------------------------------------------------------------------------------

Exclusion criteria

Exclusion Criteria:

  1. has started the ketogenic diet or was in ketosis within 3 months of wanting to enroll
  2. pregnant or nursing
  3. insulin dependent
  4. comorbidity of developmental delay
  5. in a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary programs.
  6. any one who has been hospitalized or taken clozapine at doses above 550mg over the past 3 months
  7. inability to complete baseline measurements
  8. severe renal or hepatic insufficiency
  9. cardiovascular dysfunction, including diagnosis of:

    • Congestive heart failure
    • Angina
    • Arrhythmias
    • Cardiomyopathy
    • Valvular heart disease
  10. active substance abuse with illicit drugs or alcohol and/or current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by ), with the exception of nicotine or cannabis dependence
  11. active suicidal and considered at significant risk for suicide during course of study
  12. participation in any clinical trial- within the past month or concurrent to study participation- with an drug/device and/or intervention that may interfere with study participation/evaluation of results
  13. any other medical condition that may make diet intervention dangerous as determined by the study medical team (e.g. anorexia nervosa) or assessed by study team to have insufficient control over their food intake to adhere to study diets.
  14. any medical condition that physicians or the PI believe would interfere with study participation or evaluation of results
  15. history of familial hypercholesterolemia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Arm 1: Ketogenic Diet Only

    Participants will follow 12 weeks of the ketogenic diet, with monitoring of physical and psychological health and coaching support.

    Other: LCHF Ketogenic Diet

  • Experimental
    Arm 2: DAU- Ketogenic Diet Crossover

    Participants will follow 12 weeks of their usual diet (Diet-as-Usual, DAU). Then, participants will crossover and follow 12 weeks of the ketogenic diet. Monitoring of physical and psychological health and coaching support will occur throughout participation.

    Other: LCHF Ketogenic Diet · Other: Diet-as-Usual (DAU)

Interventions

  • OtherLCHF Ketogenic Diet

    Low Carbohydrate, Moderate Protein, High Fat (LCHF) Ketogenic Dietary Intervention for 12 weeks

  • OtherDiet-as-Usual (DAU)

    Participant's usual diet

06

What researchers measure

Primary outcomes

  1. WHO-5 Well-being Index

    Change in general well-being from baseline. Self reported to measure quality of life. Assessed on 5-items, scored from 0-5 on each item, with higher scores indicating better quality of life.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  2. Functioning Assessment Short Test (FAST)

    Change in quality of life from baseline. Self reported and assessed on 24-items regarding difficulties in the experiences described. Scored from 0-3 on each item, with lower composite scores indicating better quality of life.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  3. Quality of Life Scale (QIDS)

    Change in severity of depression from baseline. Self reported on 16 items with a composite score range of 0-27 (0= no depression, 27 = very severe depression).

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

Secondary outcomes

  1. MCCB - MATRICS Consensus Cognitive Battery

    Change in cognition and brain health assessment from baseline. Scored by assessment's algorithm that compares scores within the established benchmark by age group and test. (≥ 1.5 SD below normative means = insufficient performance, ≥1 SD below normative means = subtle impaired performance in task)

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  2. Montgomery-Asberg Depression Rating Scale (MADRS)

    Change in quality of life related to cognitive function from baseline. T-score 17.3- 38.9 (high scores indicate better/desirable self-reported health).

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  3. Brief Psychiatric Assessment Scale (BPRS)

    change in severity of psychopathy; 18 conditions scored by clinician. Each of the 18 conditions/outcomes rated from 0-7 (0= not assessed, 7 = extremely severe).

    Time frame: Screening; Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  4. Patient Health Questionnaire (PHQ-9)

    Change in Depression; 9-10 items scored on composite score range 0-27 (0= no depression, 27= severe depression).

    Time frame: Screening; Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  5. Clinical Global Impressions Scale (CGI)/ Clinical Mood Monitoring

    Change in Clinical Global Impression (CGI) Psychiatric Index; 1-7 scale. (1= not at all ill, 7= among the most extremely ill patients).

    Time frame: Screening; Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  6. Young Mania Rating Scale (YMRS)

    Change in perceived stress from baseline measured by PSS-4 biweekly, a 4-item scale providing a 0-16 point composite score, with higher scores indicating greater perceived stress.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  7. Generalized Anxiety Disorder Scale (GAD-7)

    Change in General Anxiety Disorder (GAD-7) scale from Baseline. 0-15+ scale. (0= no anxiety, 15+= severe anxiety).

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  8. Pittsburgh Sleep Quality Index (PSQI)

    Change in sleep quality from baseline; 0-21 scale (\<5=good sleeper; 5+= meaningfully disturbed sleep or poor sleeper).

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  9. Epigenome

    Profiling of epigenome measured in biospecimen collected.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  10. Mitochondrial Function

    Change in mitochondrial function from baseline measured in biospecimen.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  11. Metabolome

    Change in metabolites from baseline measured in biospecimen.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  12. Proteome

    Change in proteins from baseline measured in biospecimen.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  13. Microbiome

    Change in microbes/microorganisms from baseline measured in biospecimen.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  14. Transcriptome

    Change in mRNA-based expression from baseline measured in biospecimen.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  15. Lipidome

    Change in lipids from baseline measured in biospecimen.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  16. Blood pressure

    Change in blood pressure measured continuously by wearable devices and recorded weekly/biweekly during study visits.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  17. Heart Rate Variability

    Change in heart rate variability measured continuously by wearable devices and recorded weekly/biweekly during study visits.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  18. Heart Rate

    Change in heart rate measured continuously by wearable devices and recorded. weekly/biweekly during study visits.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  19. Weight

    Change in Weight from Baseline, recorded weekly/biweekly during study visits.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  20. Waist Circumference

    Change in waist circumference from Baseline, recorded weekly/biweekly during study visits.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  21. Total Cholesterol

    Blood measurement of change in Lipid Profile (total cholesterol) from baseline.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  22. Low Density Lipoprotein Cholesterol (LDL-C)

    Blood measurement of change in Lipid Profile (LDL-C) from baseline.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  23. High Density Lipoprotein Cholesterol (HDL-C)

    Blood measurement of change in Lipid Profile (HDL-C) from baseline.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  24. Triglycerides (TG)

    Blood measurement of change in Lipid Profile (TG) from baseline.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  25. Inflammatory Marker (hs-CRP)

    Blood measurement of change in Inflammatory Marker (hs-CRP) from baseline.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  26. Insulin Resistance Measure (HOMA-IR)

    Blood measurement of change in insulin resistance from baseline.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  27. Glucose

    Blood measurement of change in Metabolic Marker (Glucose) from baseline.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

  28. Hemoglobin A1c

    Blood measurement of change in Metabolic Marker (hemoglobin A1c) from baseline.

    Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005 Oct;187:366-71. doi: 10.1192/bjp.187.4.366. PubMed 16199797 ↗

Individual participant data

Plan to share: No — No current plan to share data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 26 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Jul 2025 → Oct 2026, primary completion Jul 2028 → Dec 2028 and completion Jul 2028 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2024
First posted
Dec 27, 2024
StartActual
Oct 19, 2026was Jul 2025
Primary completionEst.
Dec 2028was Jul 2028
CompletionEst.
Jun 2029was Jul 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Stanford University is now Recruiting
Nov 16, 2026
Start date
Jul 2025→Oct 19, 2026 (actual)
Nov 16, 2026
Primary completion
Jul 2028→Dec 2028
Nov 16, 2026
Study completion
Jul 2028→Jun 2029
Nov 16, 2026
Eligibility
1 inclusion criterion added, 6 removed; 2 exclusion criteria removed
What changed in the criteria
Inclusion criteria
  • RemovedNot mild
  • Removed>40 on BPRS
  • RemovedNot mild
  • RemovedPHQ-9 > 10
  • RemovedNot mild
  • Removed>40 on BPRS
  • Added--------------------------------------------------------------------------------
Exclusion criteria
  • Removedmild BPRS at screening or baseline visits
  • Removedhistory of TBI
Nov 16, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • ChangedBefore Cambridge Cognition (CANTAB Assessment)Now MCCB - MATRICS Consensus Cognitive BatteryTime frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).
  • ChangedBefore Quality of Life in Neurological Disorders (Neuro-QOL, Cognitive Function)Now Montgomery-Asberg Depression Rating Scale (MADRS)Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).
  • ChangedBefore Perceived Stress Scale 4 (PSS-4)Now Young Mania Rating Scale (YMRS)Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Stanford University · Palo Alto, United StatesContact j•••@stanford.edu · •••0169→j•••@stanford.edu · •••0169Contact added d•••@stanford.edu · •••6733Contact added (no phone or email listed)Contact added (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Stanford University is now Recruiting
    Start date Jul 2025→Oct 19, 2026 (now actual)
    Primary completion Jul 2028→Dec 2028
    Study completion Jul 2028→Jun 2029
    Eligibility 1 inclusion criterion added, 6 removed; 2 exclusion criteria removed
    What changed in the criteria
    Inclusion criteria
    • RemovedNot mild
    • Removed>40 on BPRS
    • RemovedNot mild
    • RemovedPHQ-9 > 10
    • RemovedNot mild
    • Removed>40 on BPRS
    • Added--------------------------------------------------------------------------------
    Exclusion criteria
    • Removedmild BPRS at screening or baseline visits
    • Removedhistory of TBI
    Secondary outcomes 3 edited
    What changed in the outcomes
    • ChangedBefore Cambridge Cognition (CANTAB Assessment)Now MCCB - MATRICS Consensus Cognitive BatteryTime frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).
    • ChangedBefore Quality of Life in Neurological Disorders (Neuro-QOL, Cognitive Function)Now Montgomery-Asberg Depression Rating Scale (MADRS)Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).
    • ChangedBefore Perceived Stress Scale 4 (PSS-4)Now Young Mania Rating Scale (YMRS)Time frame: Baseline through study completion, an average of 12 weeks (Arm 1: Ketogenic Diet Only) or 24 weeks (Arm 2: DAU-Ketogenic Diet Crossover).
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Stanford University · Palo Alto, United StatesContact j•••@stanford.edu · •••0169→j•••@stanford.edu · •••0169Contact added d•••@stanford.edu · •••6733Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06748950
Responsible party
Shebani Sethi (Clinical Associate Professor, Stanford University) — Principal investigator
First posted
Dec 27, 2024
Start date
Oct 19, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Study Coordinator
Contact
jessili@stanford.edu
(650) 725-0169
Shebani Sethi, MD, ABOM
principal investigator · Stanford University
Michael Snyder, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion